NCT01883323View on ClinicalTrials.gov

Tumor-Infiltrating Lymphocytes And Low-Dose Interleukin-2 Therapy Following Cyclophosphamide And Fludarabine In Patients With Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

April 30, 2018

Study Completion Date

April 30, 2018

Conditions
Metastatic, Stage III or Stage IV, Melanoma
Interventions
DRUG

Cyclophosphamide

i.v., 60mg/kg per day for 2 days

DRUG

Fludarabine

i.v., 25mg/m2 per day for 5 days

BIOLOGICAL

Tumor-Infiltrating Lymphocytes

i.v., 1x10\^10 - 1.6x10\^11 cells

BIOLOGICAL

Low-Dose Interleukin

i.v., 125,000 IU/kg subcut per day, for 2 weeks (2 days rest between each week)

Trial Locations (1)

M5G 2M9

Princess Margaret Cancer Centre, Toronto

All Listed Sponsors
lead

University Health Network, Toronto

OTHER

NCT01883323 - Tumor-Infiltrating Lymphocytes And Low-Dose Interleukin-2 Therapy Following Cyclophosphamide And Fludarabine In Patients With Melanoma | Biotech Hunter | Biotech Hunter